Case Presentation From Vascular Division

Kaavya Mahajan, MD, Jacopo Colombo, MD

Published December 2, 2024 | Clinics in Medical Education 

Issue 4 | Volume 1 | November 2024

A 59 year old female with weight of 57 kg and BMI 20 with past medical history Cardiac: HTN, HLD, HFrEF, chronic CAD, valvular disease
Pulmonary: current smoker, active MJ use, COPD, severe pHTN.

  • Endocrine: DM
  • Kidney: ESRD on HD
  • Vascular: PAD

Perioperative Evaluation

  • Prior cardiac testing and cardiology notes reviewed

  • Patient confirmed no interval cardiology visits occurred between May and July 2024

  • Per MAR, patient’s current GDMT included metoprolol

  • Bedside TTE, lung and gastric ultrasound exam performed

  • Patient consented for GETA, CVL, PA-Catheter, a-line with high risk for perioperative cardiovascular morbidity

After an interdisciplinary discussion with anesthesia and vascular surgery teams regarding our perioperative evaluation, decision made to postpone the case due to evidence of worsening biventricular systolic function and echocardiographic signs of volume overload. Recommended further cardiac assessment and treatment of acute decompensated heart failure.

Cardiology Consulted

  • TTE: EF 16%, severe global LV hypokinesis c/w non-ischemic cardiomyopathy, RV dilation with free wall hypokinesis, moderate-severe TR (increased from 5/24), well-seated MV
  • RHC: elevated pre and postcapillary filling pressures, mean PAP 32 mmHg, PCWP 18 mmHg
  • Recommended aggressive volume removal with HD
  • Restarted on valsartan
  • Outpatient HF follow-up for advanced therapies, including Sacubitril-Valsartan initiation
  • Consider endovascular interventions without generalized anesthesia
  • Angiogram, angioplasty of popliteal and SFA conducted on hospital day #8 and #11 under MAC with precedex infusion

What is Heart Failure?

Heart failure is a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood . Most common causes of HF include ischemic heart disease, MI, HTN, valvular heart disease. Advanced stages of HF are associated with overall reduced survival. Therapeutic interventions at each stage aim to mitigate risk factors, treat underlying structural heart disease to prevent HF, reduce symptoms, morbidity and mortality. Patients with acute or chronic HF have worse outcomes as compared to patients without a history of HF. In a 2008 study utilizing Medicare claims data, amongst individuals undergoing AKA, BKA, LE bypass, or open AAA, the 30-day risk of mortality was up to twice as high for patients with history of HF compared to those without HF.

Evaluation, Management, Anesthesia Considerations of Acute Decompensated Systolic Heart Failure

CBC: Complete Blood Count; BMP: Basic Metabolic Panel; UA: Urine Analysis; UCx/BCx: Urine/Blood Culture; TSH: Thyroid Stimulating Hormone

REFERENCES

1.  Carless PA, Henry DA, Moxey AJ, O’Connell D, Brown T, Fergusson DA. Cell salvage for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010

2.  Tamura T, Waters JH, Nishiwaki K. Heparin concentration in cell salvage during heparinization: a pilot study. Nagoya J Med Sci. 2020